Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial
Bitget2026/10/22 14:05- Vera Therapeutics reported positive final ORIGIN 3 trial results for Trutakna in adults with primary IgA nephropathy.
- The treatment met all prespecified efficacy endpoints, slowing kidney function decline and reducing the risk of kidney disease progression versus placebo.
- Safety was generally comparable to placebo, with fewer serious adverse events.
- Results were presented at ASN Kidney Week 2026 on October 22 and simultaneously published in The New England Journal of Medicine.
- A supplemental biologics license application is planned for the fourth quarter of 2026, with potential full FDA approval in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple (AAPL.US) sets record highs in Q4 revenue and iPhone sales; Greater China region emerges as a concern
Apple (AAPL.US) released its financial report after the U.S. stock market closed on Monday.
Wajax Q3 Net Earnings Fall 28% Year Over Year to CAD 12 Million
US LNG exports surged to the second-highest level in history in October, with Europe accounting for 60% of demand
In October, U.S. LNG exports reached 7.92 million metric tons, only slightly below the record high of 8.01 million metric tons set in April this year, and saw a significant month-on-month increase from 7.12 million metric tons in September. Europe continues to expand its purchases of U.S. LNG, with its share surging 8 percentage points from the previous month to 60%. Analysts point out that Europe's underground gas storage facilities are nearly full; if temperatures in the Northern Hemisphere remain normal this winter, high global inventories may put downward pressure on prices.
Crypto prices
More
